NCT00304512View on ClinicalTrials.gov

A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Female Participants With Fabry Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

September 7, 2006

Primary Completion Date

May 9, 2008

Study Completion Date

May 9, 2008

Conditions
Fabry Disease
Interventions
DRUG

migalastat HCl

Trial Locations (6)

3050

Parkville

30033

Decatur

75015

Paris

RS, 90035-903

Porto Alegre

H4J 1C5

Montreal

M6 8HD

Salford

Sponsors
All Listed Sponsors
lead

Amicus Therapeutics

INDUSTRY